Understanding how MMP3 contributes to ovarian cancer resistance to cisplatin
Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer
This study is looking at how a protein called MMP3 might help ovarian cancer cells resist the chemotherapy drug cisplatin, with the hope of finding new treatments that can make the cancer more responsive to this medication.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Puerto Rico Med Sciences NIH-funded |
| Lab location | 1 site (San Juan, United States) |
| Project ID | NIH-11074110 on NIH RePORTER |
What this research studies
This research investigates the role of matrix metalloproteinase 3 (MMP3) in the resistance of ovarian cancer to the chemotherapy drug cisplatin. By analyzing cancer cells that are resistant to cisplatin, researchers aim to uncover how high levels of MMP3 correlate with faster tumor relapse. The study employs differential gene expression techniques to identify the abundance of MMP3 in resistant versus responsive cancer cells. The ultimate goal is to develop targeted therapies that can inhibit MMP3 and potentially reverse chemotherapy resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are ovarian cancer patients who have developed resistance to cisplatin treatment.
Not a fit: Patients with ovarian cancer who have not undergone cisplatin treatment or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for ovarian cancer patients who currently have limited responses to cisplatin.
How similar studies have performed: While there have been previous studies on MMP inhibitors, this research aims to explore a novel approach specifically targeting MMP3 in the context of cisplatin resistance.
Where this research is happening
San Juan, United States
- University of Puerto Rico Med Sciences — San Juan, United States (Active)
Researchers
- Principal investigator: Vivas-Mejia, Pablo Elias — University of Puerto Rico Med Sciences
- Study coordinator: Vivas-Mejia, Pablo Elias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.